Advice

Following a resubmission.

Laronidase is not recommended for use within NHS Scotland for the treatment of mucopolysaccharidosis I. Laronidase was approved by the EMEA under exceptional circumstances and has been granted orphan drug status. No information is presented in the submission to support the therapy being cost effective.

Download detailed advice29KB (PDF)

Download

Medicine details

Medicine name:
Laronidase (Aldurazyme®)
SMC ID:
100/04
Indication:
Mucopolysaccharidosis I
Pharmaceutical company
Genzyme Therapeutics Ltd
BNF chapter
Nutrition and blood
Submission type
Resubmission
Status
Not recommended
Date advice published
13 December 2004